Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 20;9(1):7599.
doi: 10.1038/s41598-019-44078-6.

Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab

Tatsuya Yoshitake  1 , Tomoaki Murakami  2 , Kiyoshi Suzuma  1 , Masahiro Fujimoto  1 , Yoko Dodo  1 , Akitaka Tsujikawa  1
Affiliations

Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab

Tatsuya Yoshitake et al. Sci Rep. .

Abstract

The early remission of diabetic macular edema (DME) often occurs in eyes treated with anti-vascular endothelial growth factor (VEGF) treatment. We retrospectively reviewed and characterized eyes with early remission of DME at six months in 80 eyes under pro re nata (PRN) intravitreal ranibizumab (IVR) injections. The number of eyes without center-involved DME gradually increased and 14 and 20 eyes achieved remission of DME at 3 or 6 months, respectively, under the PRN regimen following three monthly loading doses. In particular, eyes with early remission at 6 months had smaller CSF thickness than those without the remission before and after the treatment except at the 1-month visit (P < 0.05); however, the changes in CSF thickness did not differ between them. VA and its changes were not different between eyes with and without remission. Multivariate analysis revealed that smaller CSF thickness at baseline predicted the early remission of DME under PRN IVR injections (odds ratio, 0.989; 95% confidence interval, 0.982-0.997; P = 0.008). These data elucidate the clinical characteristics of early remission of DME under PRN IVR injections and suggest that smaller CSF thickness at baseline is a novel predictor of early remission under PRN IVR injections for DME.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The number of cases with early remission of DME following PRN IVR injections. (a) The number of eyes without center-involved DME treated with PRN IVR injections following three monthly doses. (b) Cumulative cases with early remission at individual time points.
Figure 2
Figure 2
Comparisons in functional and anatomical courses between eyes with and without early remission of DME at 6 months following PRN IVR injections. The course of the logMAR VA (a) and its improvement (b) in eyes with and without early remission of DME under PRN IVR injections following three monthly loading doses. The course of the CSF thickness (c) and its changes (d). (e) The percentage of eyes that received IVR injection at individual time points. Black = eyes with early remission of DME at 6 months. Gray = eyes without early remission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yau JW, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564. doi: 10.2337/dc11-1909. - DOI - PMC - PubMed
    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–1239. doi: 10.1056/NEJMra1005073. - DOI - PubMed
    1. Funatsu H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–77. doi: 10.1016/S0002-9394(01)01269-7. - DOI - PubMed
    1. Murakami T, Frey T, Lin C, Antonetti DA. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes. 2012;61:1573–1583. doi: 10.2337/db11-1367. - DOI - PMC - PubMed
    1. Elman MJ, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077 e1035. doi: 10.1016/j.ophtha.2010.02.031. - DOI - PMC - PubMed

Publication types

Substances